Edit
Iroko Pharmaceuticals, LLC
http://www.iroko.com/Last activity: 12.06.2014
Active - Reference to Atom.com
Iroko is dedicated to advancing the science of analgesia. Iroko Pharmaceuticals is named for the majestic West African iroko tree. Its deep roots represent strength and stability, while its leaves symbolize renewal and innovation. At Iroko, we believe it is possible to offer new options for responsible pain management. Medical and regulatory organizations have recommended the use of the lowest effective doses of NSAIDs for the shortest duration of time. We are using innovative proprietary SoluMatrix Fine Particle Technology™ to develop new drug products based on existing NSAIDs to relieve pain at lower doses. To learn more, please visit our Corporate Website.
Location: United States, Pennsylvania, Philadelphia
Employees: 51-200
Founded date: 2007
Investors 1
Mentions in press and media 6
| Date | Title | Description |
| 12.06.2014 | Iroko takes low dose approach to osteoarthritis pain meds to avoid adverse events | Osteoarthritis is one of the most common causes of disability. It affects 27 million adults, according to the Centers for Disease Control. In a phone interview with Iroko CEO John Vavricka, he pointed out that the lower dosages are especial... |
| 22.11.2013 | Iroko Pharmaceuticals Secures $75M in Debt Financing | PHILADELPHIA, PA, Global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the company has entered into a $75 million debt facility. >> Click here for more funding data on Iroko ... |
| 21.11.2013 | Iroko Pharmaceuticals Closes $75M Debt Facility | Iroko Pharmaceuticals, LLC, a Philadelphia, PA-based global specialty pharmaceutical company dedicated to advancing the science of analgesia, closed a $75m debt facility agreement with an affiliate of OrbiMed Advisors LLC. The financing wil... |
| 20.06.2013 | PTC Therapeutics joins the IPO scrum as more biotechs take advantage of receptive market | The nonsense mutation is the cause of Duchenne muscular dystrophy in about 13 percent of patients, or 2,000 people in the United States and 2,500 in the European Union. The company also plans to treat nonsense mutations in other genetic dis... |
| - | PTC Therapeutics joins the IPO scrum as more biotechs take advantage of receptive market | It may not be the most complimentary assessment of a biotech’s initial public offering to say that if PTC Therapeutics can reach its public offering target of $125 million, then the market really is coming back for IPOs. But to be sure, the... |
| - | Iroko takes low dose approach to osteoarthritis pain meds to avoid adverse events | Drug development companies have developed innovative approaches to drug formulation to avoid or reduce the adverse events that accompany pain management drugs. Iroko Pharmaceuticals has been building a portfolio of low dose Non Steroidal An... |